Implantica Expands RefluxStop™ Treatment Accessibility Across Spain

In a significant advancement for the treatment of gastroesophageal reflux disease (GERD), Implantica AG, a leader in medical technology, has announced the expansion of its RefluxStop™ procedure to new centers of excellence in Spain. The latest addition is the prestigious Hospital Vithas 9 de Octubre in Valencia, known for its excellence in digestive endoscopy and its commitment to innovative medical solutions.

RefluxStop™ Device

Introduction of RefluxStop™ in Valencia

The introduction of RefluxStop™ at Hospital Vithas 9 de Octubre represents a major milestone in the journey to provide more effective and accessible treatments for the 1 billion individuals suffering from acid reflux globally. The procedure, recently performed by Dr. Barrasa, leverages a unique mechanism that sets it apart from traditional anti-reflux surgeries.

Dr. Barrasa expressed his gratitude to the surgical team for their critical role in the successful implementation of this innovative procedure. He highlighted the urgent need for such treatments in Valencia and throughout Spain, emphasizing, “We have a massive unmet need for a surgical solution with fewer side effects.” Traditional anti-reflux surgeries often lead to uncomfortable post-surgery symptoms, which RefluxStop™ aims to minimize.

Unique Mechanism of RefluxStop™

What makes RefluxStop™ revolutionary is its ability to treat the root cause of acid reflux without the conventional approach of encircling the esophagus. Traditional surgeries often involve encircling the food passage, which can result in a range of complications, including swallowing difficulties and discomfort. In contrast, RefluxStop™ focuses on preserving the anatomical structure of the lower esophageal sphincter, thereby restoring its natural function without applying pressure.

The procedure utilizes a patented mechanism that reconstructs the essential components of the anti-reflux barrier. By maintaining the lower esophageal sphincter in its original position, it supports the body's natural ability to manage acid reflux effectively.

Growing Demand for GERD Treatments

Dr. Peter Forsell, the inventor of RefluxStop™ and CEO of Implantica, emphasized the increasing demand for surgical treatments among patients suffering from GERD. As awareness grows regarding the side effects associated with long-term proton pump inhibitor (PPI) use, more patients are seeking alternatives. He stated, “The proportion of patients with GERD is increasing across all age groups, and we're glad to see the commitment of hospitals like Vithas 9 de Octubre in advancing treatment options.”

Future Outlook for RefluxStop™ in Spain

With the recent addition of the Hospital Vithas 9 de Octubre, Implantica now boasts 13 established RefluxStop™ centers throughout Spain. This expansion underscores the company's commitment to improving health outcomes for GERD patients across various regions.

The expected benefits of introducing RefluxStop™ include fewer side effects, enhanced patient satisfaction, and a potential shift towards more effective management of GERD. As more medical facilities recognize the importance of innovative solutions, the landscape of GERD treatment in Spain is set to transform.

Conclusion

Implantica continues to pave the way in medical technology, establishing itself as a pivotal player in enhancing patient care for acid reflux. The expansion of RefluxStop™ represents not only a technical advancement but also a cultural shift in how surgical treatments are perceived and implemented within Spain’s healthcare system. With a commitment to innovation and excellence, Implantica is poised to significantly impact the lives of countless individuals suffering from GERD across the globe.

For more information about RefluxStop™ and its clinical benefits, please visit Implantica's official website.